Opinion
Video
Author(s):
Panelists discuss how the current spinal muscular atrophy (SMA) treatment landscape includes 3 options: gene therapy (onasemnogene abeparvovec [Zolgensma]) for younger patients and 2 splice modifiers (nusinersen [Spinraza] and risdiplam [Evrysdi]) for older patients.
Clinical Brief: Historical and Current Treatment Paradigms for SMA
Main Discussion Topics
Key Points for Physicians
Notable Insights
Implementation of consensus care guidelines and multidisciplinary care improved survival outcomes even before disease-modifying therapies were available, highlighting the importance of comprehensive care approaches.
Clinical Significance
The treatment paradigm for SMA has evolved from palliative care to a multifaceted approach combining disease-modifying therapies with supportive care, requiring ongoing adaptation of assessment methods to capture meaningful clinical outcomes.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.